α-synuclein Aggregation Inhibitor

PQM-164 (Compound 3e) has antioxidant activity (IC₅₀: 0.93 μM for DPPH radical). PQM-164 shows anti-inflammatory activity against 6-OHDA (HY-B1081A)-induced neuronal damage in activated microglial cells. PQM-164 decreases the accumulation of α-synuclein. PQM-164 promotes nuclear translocation of Nrf2 and its transcriptional activity. PQM-164 can be used for research of Parkinson’s disease.

D-685, a prodrug of D-520, exhibits higher in vivo anti-Parkinsonian efficacy in a reserpinized Parkinson's disease (PD) animal model than the parent D-520. D-685 reduces accumulation of human α-synuclein (α-syn) protein. D-685 exhibits facile brain penetration.

Dopal (purity>80%) is a metabolite and aldehyde neurotoxin of Dopamine (HY-B0451). Dopal (purity>80%) exhibits cytotoxicity, induces α-synuclein oligomerization and aggregation, and is closely associated with the pathogenesis of Parkinson's disease. Dopal (purity>80%) can be used in research related to Parkinson's disease.

Aerophobin-2 is a bromine compound, which can be isolated from sponge Verongia aerophoba. Aerophobin-2 inhibits aggregation of α-synuclein (α-syn) and phosphorylated α-synuclein (pSyn), exhibits neuroprotective efficacy.

NS163 is a α-Synuclein aggregation antagonist. NS163 can be used for study of Parkinson’s disease.

α-Synuclein-IN-25 is a quinone-acid hybrid and also an α-synuclein aggregation inhibitor with an IC₅₀ of 3.0 μM. α-Synuclein-IN-25 dissociates preformed α-Syn aggregates, inhibits their re-aggregation, scavenges reactive oxygen species, and reduces the formation of α-Syn inclusions in neuronal cells. α-Synuclein-IN-25 can be used in the research of Parkinson's disease.

GSD-16-24 is a lead compound that binds directly to the C-terminal IDR of α-syn monomers and fibrils, thereby preventing fibrils from binding to the receptor. GSD-16-24 can be used in Parkinson's research.